Skip to navigation Skip to content

CD30 positive systemic anaplastic large cell lymphoma program in Pharmaceutical Benefits Scheme (PBS) 012-18051139

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised brentuximab vedotin for patients with CD30 positive systemic anaplastic large cell lymphoma (sALCL).

CD30 sALCL listing dates

CD30 positive systemic anaplastic large cell lymphoma (sALCL) is a rare type of non-Hodgkin’s lymphoma.

Listing date: brentuximab vedotin - 1 December 2014.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • FAQs from Service Officers
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs